EFX vs LCTX · P/E 54, rev $5.68B vs rev $9.5M
Equifax Inc (EFX) versus Lineage Cell Therapeutics Inc (LCTX) — a side-by-side from cached financials, not a winner call.
Equifax Inc (EFX) is a consulting services company listed on US.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
Latest reported EFX revenue for 2024-12-31 was $5.68B. Net income was $607.3M. Revenue was up 7.9% from 2023-12-31 to 2024-12-31. EFX currently screens at market cap $33.00B and trailing P/E 54.0.
Latest reported LCTX revenue for 2024-12-31 was $9.5M. Net income was -$18.6M. Revenue was up 354.9% from 2023-12-31 to 2024-12-31. LCTX currently screens at market cap $213.6M.
EFX currently screens at market cap $33.00B and trailing P/E 54.0. LCTX currently screens at market cap $213.6M.
Not investment advice. Open the EFX and LCTX stock pages for the full models.
Not investment advice.